NCX 1000: Phase IIa started

NICOX began a double-blind, placebo-controlled, dose-escalation, Canadian Phase IIa trial. Patients will receive either 500 mg, 1,000 mg, 2,000 mg NCX 1000 or placebo as the first 3 doses during the f...